초록 ▼

A bioadhesive composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient

A bioadhesive composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).

대표청구항 ▼

1. A bioadhesive, controlled and sustained release, progressive hydration pharmaceutical composition comprising: an effective amount of terbutaline, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer, wherein said composition is formulated to de

1. A bioadhesive, controlled and sustained release, progressive hydration pharmaceutical composition comprising: an effective amount of terbutaline, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer, wherein said composition is formulated to deliver said terbutaline to the bloodstream of a mammal through a mucosal surface of the mammal. 2. The composition of claim 1, wherein said terbutaline is present in an amount of about 4 mg/per unit dosage of composition. 3. The composition of claim 1, wherein said terbutaline is present in an amount of about 2 mg/per unit dosage of composition. 4. The composition of claim 1, wherein the mucosal surface is the vagina, and said water insoluble, water-swellable cross-linked polycarboxylic polymer is Polycarbophil. 5. The composition of claim 2, wherein the mucosal surface is the vagina, and said water insoluble, water-swellable cross-linked polycarboxylic polymer is Polycarbophil. 6. The composition of claim 3, wherein the mucosal surface is the vagina, and said water insoluble, water-swellable cross-linked polycarboxlic polymer is Polycarbophil. 7. The composition of any one of claims 4, 5, or 6, wherein said water soluble polymer is carbomer 974P, and said composition further comprises lactose, hydroxypropylmethylcellulose, corn starch, talc, silica, and magnesium stearate. 8. A method of delivering to a mammal an effective amount of terbutaline via a controlled and sustained release, progressive hydration bioadbesive pharmaceutical composition through a mucosal surface of the mammal, comprising said terbutaline, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer. 9. The method of claim 8, wherein said terbutaline is present in an amount of about 4 mg/per unit dosage of said composition. 10. The method of claim 8, wherein said terbutaline is present in an amount of about 2 mg/per unit dosage of composition. 11. The method of claim 8, wherein the mucosal surface is the vagina, said water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil, said water soluble polymer is carbomer 974P, and said composition further comprises lactose, hydroxypropylmethylcellulose, corn starch, talc, silica, and magnesium stearate. 12. The method of claim 9, wherein the mucosal surface is the vagina, said water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil, said water soluble polymer is carbomer 974P, and said composition further comprises lactose, hydroxypropylmethylcellulose, corn starch, talc, silica, and magnesium stearate. 13. The method of claim 10, wherein the mucosal surface is the vagina, said water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil, said water soluble polymer is carbomer 974P, and said composition further comprises lactose, hydroxypropylmethylcellulose, corn starch, talc, silica, and magnesium stearate.